The growing Glycated Albumin Assay Market is estimated to witness high growth owing to increasing prevalence of diabetes
![]() |
Glycated Albumin Assay Market |
Glycated
albumin assay products are used for the detection and monitoring of glycated
albumin levels in blood samples of diabetic patients. Glycated albumin assay
helps in effective glucose management and prevent complications associated with
uncontrolled diabetes. The global Glycated Albumin Assay Market is estimated to
be valued at US$ 150 million in 2023 and is expected to exhibit a CAGR of 20%
over the forecast period 2024 to 2031, as highlighted in a new report published
by Coherent Market Insights.
Market Opportunity
Increasing prevalence of diabetes: The increasing prevalence of diabetes
globally has augmented the demand for efficient glucose management and
monitoring. As per International Diabetes Federation, approximately 7.5% of the
global population aged 20-79 years, which is equivalent to 537 million adults
were living with diabetes in 2021. The rising diabetes burden has opened vast
opportunities for glycated albumin assay products used for effective glycemic
control and management in diabetic patients. The growing incidence of diabetes
will fuel the demand for glycated albumin assay products over the forecast
period.
Porter's Analysis
Threat of new entrants: The threat of new entrants is moderate as it requires
strong technical expertise and high capital investments to develop new methods
and assays for glycated albumin detection. However, barriers to entry are
lowered by opportunities for partnership with established players.
Bargaining power of buyers: The bargaining power of buyers is high given the
presence of many assay providers. Buyers can negotiate on price and demand
additional services.
Bargaining power of suppliers: The bargaining power of suppliers is low as raw
materials for glycated albumin assays such as antibodies and reagents are
available from numerous sources globally.
Threat of new substitutes: The threat of substitutes is low as glycated albumin
is the most accurate potential alternative to HbA1c for diabetes monitoring.
Other albumin-based indicators cannot replace its effectiveness.
Competitive rivalry: Competition in the market is intense as major players
compete based on product reliability, sensitivity, pricing and customer
support.
SWOT Analysis
Strengths: Advanced glycated albumin assays offer reliable, precise measurement
without being affected by variables like red blood cell lifespan.
Weaknesses: High costs of assays limit adoption in resource-poor regions.
Complex pre-analytical requirements can cause errors.
Opportunities: Growing geriatric population and diabetes prevalence increases
demand. Point-of-care tests allow monitoring in remote areas.
Threats: Stringent regulatory approvals delay product launches. Reimbursement
policies vary globally affecting uptake.
Key Takeaways
The Global
Glycated Albumin Assay Market Demand is expected to witness high growth
over the forecast period of 2024 to 2031.
The
market in North America currently dominates owing to the strong presence of
leading assay providers and rising diabetes prevalence. Europe and Asia Pacific
are the fastest growing regions with increasing healthcare investments and
expansions by major players.
Key players operating in the Glycated Albumin Assay Market include Asahi Kasei
Pharma, DIAZYME, Abnova, LifeSpan, Exocell, BSBE, Medicalsystem, Maccura,
Leadman, Simes Sikma and NINGBO PUREBIO. These players collectively account for
over 50% of the global market share. The market leaders focus on new product
launches, approvals and partnerships to strengthen their geographical presence.
For more details on the report, Read- https://www.ukwebwire.com/global-glycated-albumin-assay-market-growth-demand-and-overview/
Get more insights on this topic: https://lotstoexpress.com/gummy-bliss-tasty-health-booster-for-a-vibrant-you-chewable-wellness-wonder/
Comments
Post a Comment